Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Summary not available.
Zimmer Biomet Holdings (NYSE: ZBH) announced the filing of a Form 10 with the SEC for the spinoff of its Dental and Spine businesses into a new company named ZimVie. The Form 10 outlines ZimVie's business strategy and historical financials. ZimVie will hold a virtual Investor Day on February 7, 2022, featuring insights on its market opportunities and financial outlook. The spinoff aims to optimize resource allocation and is expected to close in Q1 2022. ZimVie will focus on dental and spine markets, headquartered in Westminster, Colorado.
Zimmer Biomet Holdings (NYSE: ZBH) will host a fourth quarter earnings conference call on February 7, 2022, at 8:30 a.m. ET. A detailed earnings report will be available at 6:30 a.m. ET on the same day. Investors can access the live audio webcast via Zimmer Biomet's Investor Relations website. For those wishing to join via telephone, calls can be made to (888) 312-9837 in the U.S., using conference ID 7278985. A recording will be available for replay until March 31, 2022.
ZBH announced that Chairman, President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:00 p.m. ET. The presentation will be accessible via a live webcast on Zimmer Biomet's Investor Relations website, with a replay available post-conference. Zimmer Biomet is recognized for its innovative medical technology solutions aimed at improving patient mobility and healthcare outcomes, supported by over 90 years of industry experience.
Zimmer Biomet Holdings (NYSE: ZBH) has priced its cash tender offers for certain outstanding senior notes, which include its 3.700% notes due 2023 and various other notes maturing from 2025 to 2045. As of November 29, 2021, approximately $211.48 million of the 2023 notes were tendered. The total amount for the maximum purchase price for eligible notes has been set at about $1.93 billion, following amendments. The tender offers will expire on December 13, 2021, and the early settlement is expected on December 1, 2021.
Zimmer Biomet Holdings announced early results of its tender offers for its senior notes, increasing the aggregate maximum purchase price from $1.5 billion to encompass all validly tendered notes at priority levels 1 and 2. Notably, approximately $211.48 million of its 3.700% Senior Notes due 2023 were validly tendered and will be accepted for purchase, with an early settlement date expected on December 1, 2021. The tender offers will remain open until December 13, 2021, and the offers are subject to specific terms outlined in the Offer to Purchase.
Zimmer Biomet announced that Chairman, President and CEO Bryan Hanson, along with Executive VP and CFO Suky Upadhyay, will present at the Evercore ISI's 4th Annual HealthCONx Conference on December 2, 2021, at 1:00 PM ET. A live webcast will be available on Zimmer Biomet's Investor Relations website and will be archived for later viewing. The company focuses on maximizing mobility and improving health through innovative medical technologies.
Zimmer Biomet Holdings has declared a quarterly cash dividend of $0.24 per share for Q4 2021. This dividend will be paid on or about January 31, 2022, to stockholders who are on record as of December 28, 2021. As a key player in the medical technology sector, Zimmer Biomet aims to enhance health and mobility through innovative products and integrated technologies. The company operates in over 25 countries and has a track record of 90+ years in the industry, focused on providing quality solutions to healthcare providers and patients.
Zimmer Biomet Holdings (ZBH) announced cash tender offers for its outstanding debt securities, including a buyback of 3.700% Senior Notes due 2023 and up to $1.5 billion of other senior notes. The offers, aimed at reducing outstanding debt, will expire on December 13, 2021. The company has set up staggered acceptance priority levels for the notes and established tender caps for certain series. Payments will be made based on a Total Consideration calculation that incorporates early tender incentives. All securities will be retired and canceled upon purchase.
Zimmer Biomet reported Q3 2021 net sales of $1.924 billion, a 0.3% decline from the prior year. Despite challenges, the company showed resilience with 1.7% growth from Q3 2019. Net earnings were $145.6 million, with an adjusted diluted EPS of $1.81. Key highlights include FDA clearance for Persona IQ, a smart knee implant, and the ROSA Hip System for robotic-assisted surgery. The company has updated its 2021 financial guidance, projecting reduced revenue growth of 11.3% - 12.5% and adjusted diluted EPS of $7.32 - $7.47.